SCHEMBL9612401

SCHEMBL9612401

O=Cc1ccc(-c2c3ccccc3cc3c2ccc2c(-c4c5ccccc5c(-c5ccccc5)c5ccccc45)cccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.46
ALOX5 P09917 2/20 0.38
GPR84 Q9NQS5 2/20 0.37
ESR1 P03372 3/20 0.37
ESR2 Q92731 3/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
CES1 P23141 1/20 0.36
HSD17B1 P14061 2/20 0.36
HSD17B2 P37059 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ELANE P08246 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2855126 0.95 SOS1 (0.43) SOS1ALOX5GPR84ESR1ESR2
SCHEMBL2863928 0.89 SOS1 (0.46) SOS1GPR84MEN1KMT2ALMNA
SCHEMBL3000947 0.87 SOS1 (0.53) SOS1ALOX5GPR84ESR1ESR2
SCHEMBL26372840 0.84 DRD1 (0.41) MEN1KMT2ALMNAHPGDCYP1A2
SCHEMBL2991961 0.82 SOS1 (0.48) SOS1ALOX5GPR84ESR1ESR2
SCHEMBL3005629 0.82 SOS1 (0.50) SOS1ALOX5GPR84ESR1ESR2
SCHEMBL4821274 0.81 ALOX5 (0.50) ALOX5GPR84ESR1ESR2MEN1
SCHEMBL30800593 0.81 ALOX5 (0.50) ALOX5GPR84ESR1ESR2MEN1
SCHEMBL16381821 0.79 ALDH1A1 (0.54) MEN1KMT2ALMNAKDM4EDRD1
SCHEMBL2455000 0.78 ESR1 (0.47) SOS1ALOX5ESR1ESR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
EP-2148909-B1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-05-30 EP disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed
WO-2008145239-A2 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES KCNT1, KCNC1, TMEM109 SOS1 3965/4885ALOX5 2923/4885GPR84 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.